Article

Co-mutation landscape and prognostic impact of genomic complexity in EGFR-mutant non-small cell lung cancer

2026-08-10

Abstract excerpt

Clinical and genomic data of patients with EGFR-mutant NSCLC were collected from publicly available cBioPortal cohorts. Cohort composition, stage availability, recurrent co-mutations, and study-origin heterogeneity were evaluated. Patients harboring EGFR Del19 or L858R mutations and available survival information were included for survival analyses. Genomic landscapes were analyzed using a standardized Del19/L858R...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: dcef1707-6b28-55c4-b09f-695e4ad907c6
DOI: 10.1186/s12885-026-16715-7

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Co-mutation landscape and prognostic impact of genomic complexity in EGFR-mutant non-small cell lung cancerDOI 10.1186/s12885-026-16715-7Read

Clinical factors and molecular co-alterations impact outcomes in patients receiving first-line osimertinib for EGFR-mutated non-small cell lung cancer.Semantic proximity Read

TP53 Co-Mutation Status Association with Clinical Outcomes in Patients with EGFR-Mutant Non-Small Cell Lung CancerSemantic proximity Read

Molecular Heterogeneity Analysis and Prognostic Stratification of Driver-Gene mutated NSCLC Based on Concurrent Alteration ProfilesSemantic proximity Read

Risk stratification of EGFR+ lung cancer diagnosed with panel-based next-generation sequencing.Semantic proximity Read

The significance of co-mutations in EGFR-mutated non-small cell lung cancer: Optimizing the efficacy of targeted therapies?Semantic proximity Read

Decoding the Clinical and Molecular Signatures of EGFR Common, Compound, and Uncommon Mutations in NSCLC: A Brief Report.Semantic proximity Read

Comprehensive characterization and clinical impact of concomitant genomic alterations in EGFR-mutant NSCLCs treated with EGFR kinase inhibitors.Semantic proximity Read

EGFR G719X + S768I co-mutations in NSCLC: genomic landscape and differential responses to EGFR-TKIs in a large real-world cohort.Semantic proximity Read

Clinical and Genomic Determinants of Survival in EGFR-Mutant Non-Small Cell Lung Cancer: An Integrated Analysis of UK Biobank and cBioPortal CohortsSemantic proximity Read

TP53 co-mutations are associated with elevated PD-L1 expression and high tumor mutational burden in non-small cell lung cancer: insights from comprehensive genomic profilingSemantic proximity Read

EGFR-mutant lung adenocarcinoma harboring co-mutational tumor suppressor genes predicts poor prognosis.Semantic proximity Read

Exploring the Cause of Survival Disparities in EGFR-mutated Lung Cancer Subtypes: Unraveling Distinctive Genomic and Phenotypic Features of 19Del and L858R Mutation SubtypesSemantic proximity Read